GSK plc (GLAXF)
OTCMKTS
· Delayed Price · Currency is USD
18.46
+1.14 (6.58%)
Apr 24, 2025, 11:39 AM EDT
GSK plc Employees
GSK plc had 68,629 employees as of December 31, 2024. The number of employees decreased by 1,583 or -2.25% compared to the previous year.
Employees
68,629
Change (1Y)
-1,583
Growth (1Y)
-2.25%
Revenue / Employee
$572,359
Profits / Employee
$46,973
Market Cap
74.22B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 68,629 | -1,583 | -2.25% |
Dec 31, 2023 | 70,212 | 812 | 1.17% |
Dec 31, 2022 | 69,400 | -20,696 | -22.97% |
Dec 31, 2021 | 90,096 | -3,970 | -4.22% |
Dec 31, 2020 | 94,066 | -5,371 | -5.40% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 3,116 |
Northwest Biotherapeutics | 25 |
Elite Pharmaceuticals | 64 |
Glass House Brands | 374 |
CytoDyn | 9 |
American Oncology Network | 1,914 |
Longduoduo Company | 49 |
GSK plc News
- 3 days ago - LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed - FXEmpire
- 7 days ago - UK approves combination therapies of GSK's blood cancer drug Blenrep - Reuters
- 7 days ago - Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease - GlobeNewsWire
- 7 days ago - AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices - Business Wire
- 7 days ago - GSK’s meningococcal vaccine gets positive recommendation from ACIP - Seeking Alpha
- 7 days ago - GSK's 5-in-1 Meningococcal Vaccine PENMENVY Receives Positive Recommendation from US Advisory Committee on Immunization Practices - Business Wire
- 9 days ago - GSK is misleading prescription information on Omjjara, PMCPA says - Seeking Alpha
- 9 days ago - GSK in breach for misleading prescribing information on Omjjara, industry body says - Reuters